


What is claimed is:

1. A compound of Formula VIb1:



Formula VIb1

or a pharmaceutically acceptable salt thereof,

wherein:

R^{1b1} is ~~alkyl, aryl,~~ imidazolyl, N-methyl-2-imidazolyl, N-methyl-4-imidazolyl, 2-pyrimidinyl or 4-pyrimidinyl;

R^{8b1} is H or alkyl;

R^{9b1} is aryl, heteroaryl, heterocyclyl, halo, cyano, thiocyanate, selenocyanate, trifluoromethoxy, azide, C(O)R⁴, or S(O)_pR⁴;

R⁴ is hydrogen, hydroxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyloxy, cycloalkyloxy, aralkoxy, or -NR⁶R⁷;


R⁶ and R⁷ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, or R⁶ and R⁷ are combined to form a cyclic structure including the nitrogen atom to which they are both attached; and

p is 0-2; and

wherein each alkyl, aryl, heteroaryl, heterocyclyl, haloalkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyloxy, cycloalkyloxy, aralkoxy, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl,

arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, is optionally substituted with one or more substituents.

2. A compound of Formula VIb1:



Formula VIb1

or a pharmaceutically acceptable salt thereof,

wherein:

R^{1b1} is alkyl, ~~aryl~~, heteroaryl, or NR⁶R⁷;

R^{8b1} is H or alkyl;


R^{9b1} is ~~alkyl or~~ cycloalkyl;

R⁴ is hydrogen, hydroxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyloxy, cycloalkyloxy, aralkoxy, or -NR⁶R⁷;

R⁶ and R⁷ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, or R⁶ and R⁷ are combined to form a cyclic structure including the nitrogen atom to which they are both attached; and

~~p is 0-2~~wherein each alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, alkynyl, heterocyclyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, is optionally substituted with one or more substituents.

3. The compound of or claim 2, wherein R^{1b1} is pyridyl, imidazolyl, N-methyl-2-imidazolyl, N-methyl-4-imidazolyl, 2-pyrimidinyl or 4-pyrimidinyl.
4. The compound of claim 1 or claim 2, wherein R^{1b1} is imidazolyl.
5. A compound of Formula VIb1:



Formula VIb1

or a pharmaceutically acceptable salt thereof,

wherein:

R^{1b1} is pyridinyl;

R^{8b1} is alkyl;

R^{9b1} is substituted phenyl, heteroaryl, heterocyclyl, fluoro, chloro, iodo, $C(O)R^4$ or $S(O)_pR^4$, wherein the heteroaryl group is not a substituted pyrazole;

R^4 is hydrogen, hydroxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyloxy, cycloalkyloxy, aralkoxy, or $-NR^6R^7$;

R^6 and R^7 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, or R^6 and R^7 are combined to form a cyclic structure including the nitrogen atom to which they are both attached; and

p is 0-2; or

wherein


R^{1b1} is 2-pyridinyl;


R^{8b1} is H;


R^{9b1} is heteroaryl or heterocyclyl, wherein the heteroaryl group is not a substituted pyrazole; and


~~R⁶ and R⁷ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocycloalkyl, or R⁶ and R⁷ are combined to form a cyclic structure including the nitrogen atom to which they are both attached wherein each alkyl, heteroaryl, heterocyclyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyoxy, cycloalkyloxy, aralkoxy, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, is optionally substituted with one or more substituents.~~






6. The compound of any one of claims 1-5, wherein the compound is selected from the group consisting of:






















7. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:































8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7 and a pharmaceutically acceptable carrier, diluent or excipient.

9. A compound for use in a method of treatment, prevention or amelioration of one or more symptoms of cancer~~inhibiting the function of one or more members of the Ras superfamily,~~ wherein the compound is ~~includes~~ the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7, ~~the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7 is to be administered~~ said compound or pharmaceutically acceptable salt thereof is to be administered to a subject; ~~wherein the administered compound or pharmaceutically acceptable salt thereof of any one of claims 1-7 inhibits the function of one or more members of the Ras superfamily.~~

~~10. The compound for use of claim 9, wherein the subject has cancer.~~

~~11. The compound for use of claim 10, wherein the inhibiting the function of one or more members of the Ras superfamily is a treatment, prevention or amelioration of one or more symptoms of cancer in the subject.~~

~~1210.~~ The compound for use of ~~claim 9-claim 10 or claim 11~~, wherein the cancer is a blood cancer, hepatocellular carcinoma, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, small intestine cancer, biliary tract cancer, endometrium cancer, skin cancer (melanoma), cervix cancer, urinary tract cancer, or glioblastoma.

~~11. A compound for use in a method of treatment, prevention or amelioration of one or more symptoms of inflammatory disease, wherein the compound is the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7, said compound or pharmaceutically acceptable salt thereof to is to be administered to a subject.~~

~~12. The compound for use of claim 11, wherein the inflammatory disease is gastritis, schistosomiasis, cholangitis, chronic cholecystitis, pelvic inflammatory disease, chronic cervicitis, osteomyelitis, inflammatory bowel disease, reflux esophagitis, Barrett's esophagus, bladder inflammation (cystitis), asbestosis, silicosis, gingivitis, lichen pl anus, pancreatitis, protease mutation, lichen sclerosis, slaladenitis, bronchitis, Sjogren syndrome, Hashimoto's thyroiditis, Alzheimer's disease (AD), ankylosing spondylitis, arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus, erythematous (SLE), nephritis, Parkinson's disease, or ulcerative colitis.~~

~~13. A compound for use in a method of treatment, prevention or amelioration of one or more symptoms of rasopathy, wherein the compound is the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7, said compound or pharmaceutically acceptable salt thereof is to be administered to a subject.~~

14. The compound for use of claim 13, wherein the rasopathy is neurofibromatosis type 1, Noonan's syndrome or Costello syndrome.

15. A compound for use in a method of treatment, prevention or amelioration of one or more symptoms of fibrotic disease, wherein the compound is the compound or pharmaceutically acceptable salt thereof of any one of claims 1-7, said compound or pharmaceutically acceptable salt thereof is to be administered to a subject.

~~13.~~—The compound for use of any one of claims 9-12, wherein the one or more members of the Ras superfamily is Ras protein.

16.14. The compound for use of any one of claims 9-15-claim 13, wherein the compound of any one of claims 1-7 inhibits GTP binding to the Ras protein GTP binding domain with greater than 25% inhibition at 20 μ M-20 μ M in a cell-free assay.

17.15. The compound for use of claim 16-claim 14, wherein the Ras protein is HRAS, KRAS, or NRAS, or a mutant thereof.